MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-25-2026
Edwards Lifesciences Corporation Cost of Revenue 2011-2026 | EW
Cost of Revenue is a financial metric that reflects all direct costs associated with the production of goods or the provision of services that directly led to revenue during the reporting period. It is the total amount of expenses incurred by the company to deliver its products or services, including both production costs and related expenses necessary for delivery or customer support.What is included in the cost of revenue
| Cost Category | Examples |
|---|---|
| Production Costs | Materials, wages of production staff, depreciation of equipment |
| Service and Support | Customer service, user support, technical assistance |
| Delivery and Logistics | Packaging, delivery of goods to customers |
| Hosting and Infrastructure | Servers, cloud platforms (especially for IT and SaaS companies) |
| Content and Licenses | License purchases, production royalties (e.g., in streaming services) |
Importance of the Metric
- Helps to understand how costly the revenue-generating process is.
- A high cost of revenue may indicate:
Poor cost control
Low operational efficiency - A low cost of revenue combined with high revenue indicates high profitability and business competitiveness.
Annual Cost of Revenue Edwards Lifesciences Corporation
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.33 B | 1.12 B | 978 M | 724 M | 1.25 B | 1.08 B | 1.11 B | 939 M | 875 M | 797 M | 617 M | 626 M | 517 M | 491 M | 490 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.33 B | 490 M | 863 M |
Quarterly Cost of Revenue Edwards Lifesciences Corporation
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 345 M | 344 M | 302 M | - | 263 M | 276 M | 287 M | - | 251 M | 257 M | 330 M | - | 254 M | 269 M | 299 M | - | 312 M | 334 M | 293 M | - | 281 M | 238 M | 265 M | - | 292 M | 304 M | 232 M | - | 225 M | 246 M | 234 M | - | 213 M | 211 M | 216 M | - | 201 M | 202 M | 180 M | - | 147 M | 159 M | 136 M | - | 168 M | 151 M | 146 M | - | 128 M | 124 M | 121 M | - | 112 M | 130 M | 127 M | - | 126 M | 128 M | 117 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 345 M | 112 M | 222 M |
Cost of Revenue of other stocks in the Medical devices industry
| Issuer | Cost of Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Align Technology
ALGN
|
1.2 B | $ 186.27 | -0.14 % | $ 13.9 B |  USA |
 |
Axonics Modulation Technologies
AXNX
|
76 M | - | - | $ 3.31 B | USA |
 |
Aziyo Biologics
AZYO
|
5.7 M | - | 1.37 % | $ 20.5 M | USA |
 |
Bruker Corporation
BRKR
|
1.72 B | $ 39.36 | -0.3 % | $ 5.86 K | USA |
 |
BioSig Technologies
BSGM
|
57 K | - | 37.08 % | $ 85.7 M | USA |
 |
Acutus Medical
AFIB
|
10.3 M | - | -26.83 % | $ 2.62 M | USA |
 |
Conformis
CFMS
|
38.8 M | - | - | $ 16.4 M | USA |
 |
Avinger
AVGR
|
5.65 M | - | -20.74 % | $ 369 K | USA |
 |
AdaptHealth Corp.
AHCO
|
2.64 B | $ 12.64 | -0.12 % | $ 1.71 B | USA |
 |
Allied Healthcare Products
AHPI
|
24.5 M | - | 3.58 % | $ 2.21 M | USA |
 |
Cytosorbents Corporation
CTSO
|
10.6 M | $ 0.61 | 3.16 % | $ 38 M | USA |
 |
EDAP TMS S.A.
EDAP
|
37.6 M | $ 3.57 | 1.42 % | $ 134 M |  France |
 |
Boston Scientific Corporation
BSX
|
6.22 B | $ 63.93 | -1.04 % | $ 94.6 B | USA |
 |
Apollo Endosurgery
APEN
|
34.4 M | - | - | $ 475 M | USA |
 |
Cardiovascular Systems
CSII
|
63.4 M | - | 0.15 % | $ 844 M | USA |
 |
Eargo
EAR
|
23 M | - | - | $ 10.2 M | USA |
 |
ClearPoint Neuro
CLPT
|
14.3 M | $ 10.59 | 1.25 % | $ 300 M | USA |
 |
Dynatronics Corporation
DYNT
|
21.4 M | - | 14.99 % | $ 929 K | USA |
 |
Electromed
ELMD
|
14 M | $ 25.34 | -1.46 % | $ 214 M | USA |
 |
Second Sight Medical Products
EYES
|
11.4 M | - | -0.97 % | $ 54.4 M | USA |
 |
GBS
GBS
|
1.81 M | - | -0.57 % | $ 7.12 M | USA |
 |
LENSAR
LNSR
|
31.3 M | $ 5.93 | -5.12 % | $ 70.9 M | USA |
 |
Neovasc
NVCN
|
556 K | - | - | $ 111 M |  Canada |
 |
OrthoPediatrics Corp.
KIDS
|
63.7 M | $ 16.77 | -6.05 % | $ 393 M | USA |
 |
Globus Medical
GMED
|
958 M | $ 92.92 | -1.7 % | $ 12.6 B | USA |
 |
Helius Medical Technologies
HSDT
|
583 K | $ 1.99 | 2.58 % | $ 1.21 M | USA |
 |
Butterfly Network
BFLY
|
33.2 M | $ 5.52 | 13.46 % | $ 1.17 B | USA |
 |
Inogen
INGN
|
194 M | $ 6.54 | 5.48 % | $ 174 M | USA |
 |
IRIDEX Corporation
IRIX
|
33.4 M | $ 1.03 | -0.96 % | $ 17.4 M | USA |
 |
BIOLASE
BIOL
|
32.4 M | - | -13.19 % | $ 166 K | USA |
 |
Delcath Systems
DCTH
|
11.8 M | $ 10.87 | -1.14 % | $ 389 M | USA |
 |
Inspire Medical Systems
INSP
|
133 M | $ 57.13 | 0.83 % | $ 1.68 B | USA |
 |
CONMED Corporation
CNMD
|
624 M | $ 38.19 | -3.22 % | $ 1.19 B | USA |
 |
LivaNova PLC
LIVN
|
448 M | $ 64.79 | -0.54 % | $ 3.53 B |  Britain |
 |
Integer Holdings Corporation
ITGR
|
1.35 B | $ 88.46 | 0.74 % | $ 3.07 B | USA |
 |
Invacare Corporation
IVC
|
566 M | - | - | $ 24.7 M | USA |
 |
Penumbra
PEN
|
461 M | $ 332.04 | -0.11 % | $ 12.9 B | USA |
 |
Sintx Technologies
SINT
|
557 K | $ 2.65 | -3.28 % | $ 7.35 M | USA |